DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on April 20, 2026 has been entered.
Claim Rejections - 35 USC § 103
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Claims 7-26 are rejected under 35 U.S.C. 103 as being unpatentable over Okami (US 5,104,919) in view of Kato (US 2018/0134871 A1) and Tasaki (US 2014/0039106 A1).
Regarding claim 7, Okami teaches a curable silicon composition comprising:
An organopolysiloxane containing at least two silicon-bonded unsaturated aliphatic hydrocarbon groups (Abstract), which reads on the claimed component “(A).”
A vinyl group-containing organocyclopolysiloxane (Abstract), which reads on the claimed component “(E-2).”
An organohydrogenpolysiloxane containing at least two silicon-bonded hydrogen atoms in the molecule (Abstract), which reads on the claimed component “(B).”
A platinum family metal catalyst (Abstract), which reads on the claimed component “(C).”
Okami further teaches the incorporation of a reaction retarder which may optionally comprise ethynylcyclohexanol (col. 6, lines 13-17), which is an acetylene alcohol compound and which reads on the claimed component “(E-1).”
Okami teaches that the inventive curable composition is prepared as a two-pack system (col. 6, lines 30-31), wherein components A, B, and D are packaged together (corresponding to a first composition containing the claimed components “(A),” “(E-2),” and “(C),” which aligns with the claimed “composition X”), and components A, C, and E are packaged together (corresponding to a second composition containing the claimed components “(A),” “(B),” and “(D)”, which aligns with the claimed “composition Y”) (col. 6, lines 30-34).
Okami teaches a triazole compound (Abstract), which includes benzotriazole compounds (col. 5, lines 22-41), but differs from claim 7 because it is silent with regard to the particularly specified benzotriazole of “general formula (T).”
In the same field of endeavor, Kato teaches a curable silicone rubber composition containing an organopolysiloxane, an organohydrogenpolysiloxane, a platinum catalyst, and a benzotriazole (Abstract), wherein the benzotriazole may be the same as the claimed “general formula (T)” ([0036], [Chemical Formula 6]). It is prima facie obvious to substitute equivalents known in the art as suitable for the same purpose (See MPEP 2144.06). Therefore, it would have been obvious to one having ordinary skill in the art at the time of filing to substitute the claimed benzotriazole, as taught by Kato, into the formulation of Okami, as Kato teaches it as a suitable benzotriazole for use in addition curable silicone formulations.
Okami further differs from claim 7 because, while it teaches the incorporation of a reaction retarder which reads on the claimed component “(E-1),” it is silent with regard to which part of the two-part system said component should be added to.
In the same field of endeavor, Tasaki teaches a two-part curable liquid silicone rubber composition comprising two liquid compositions (Abstract), and teaches that curing inhibitors may be added to the first and/or the second liquid of a two-part composition to enhance the storage stability and handling/workability of the formulation ([0048]). Tasaki also teaches ethynylcyclohexanol as a suitable curing inhibitor, just as Okami does ([0048]). Therefore, it would have been obvious to one having ordinary skill in the art at the time of filing to incorporate the ethynylcyclohexanol cure inhibitor of Okami into the second part of the two-part system of Okami, as Tasaki teaches that said inhibitor may be added in either part. Doing so would result in a two-part system taught by Okami wherein each of the two parts are comprised of the same components as the claimed compositions “X” and “Y.”
Turning to the compositional limitations of claim 1, Okami teaches the following:
Component A is arbitrarily set to 100 parts, which is identical to the claimed amount of claimed component “(A),” establishing a prima facie case of obviousness. Component C (which reads on the claimed component (B)) is added in amounts such that the number of SI-H atoms ranges between 0.5 and 5 times the amount of silicon-bound vinyl groups in the formula (col. 3, lines 31-34), and exemplifies that quantity in Example 1, wherein 5.0 parts of methylhydrogenpolysiloxane are included (col. 6, lines 67-68), which falls within the claimed range of “0.2 to 20 parts by mass,” establishing a prima facie case of obviousness. Component D (which reads on the claimed component (C)) is added in amounts of 0.5 to 1,000 ppm based on the sum total of components A and B (col. 5, lines 1-5), which encompasses the claimed range of “0.5 to 500 ppm,” establishing a prima facie case of obviousness.
Finally, the amounts of component E (which reads on the claimed component (D)) range from 0.005 to 1 part per 100 parts of component A (col. 5, lines 42-45). Okami additionally exemplifies the amount of component E as 0.03 parts of a 50% benzotriazole solution in ethanol within Example 1 (col. 7, lines 10-25). Within the same formulation, 30 ppm of platinum based on the component A is also added (col. 7, lines 10-12). Using grams as a proxy for parts, this corresponds to 3 mg of platinum (30 ppm equates to 30 milligrams of platinum per 1000 grams of component A, and since 100 grams of component A are included, this corresponds to 3 milligrams of platinum). Given the elemental weight of platinum as 195.08 g/mol, this corresponds to 1.54 E -5 moles of platinum in Example 1. Furthermore, the aforementioned 0.04 parts of a 50% solution of benzotriazole converts to 0.015 grams of benzotriazole (since half is ethanol, then only half of the 0.03 grams is benzotriazole). Using the molecular weight of benzotriazole (119.13 g/mol), this corresponds to 1.26 E -4 moles of benzotriazole. The ratio of benzotriazole to platinum atoms in this example is therefore 1.26 E -4 / 1.54 E -5 = approximately 8.2 moles of benzotriazole per mole of platinum atoms, which falls within the claimed range of “2 to 100,” establishing a prima facie case of obviousness.
Claimed components “(E-1)” and “(E-2),” are not limited in terms of compositional amounts. Therefore, the teachings of Okami in view of Tasaki read on the claimed composition.
Regarding the newly added limitation requiring “a mole ratio between: hydrogen atoms bonded to a silicon atom within the organohydrogenpolysiloxane of the component (B); and a total amount of the alkenyl groups bonded to a silicon atom in the components (A) and (B) (SiH group / alkenyl group) is greater than 2.0 and up to and including 5,” Okami teaches that the number of silicon-bonded hydrogen atoms within inventive component (C) ranges from 0.5 to 5 times the total number of alkenyl groups within inventive components (A) and (B) (co. 4, lines 36-43), which encompasses the claimed range of “greater than 2.0 and up to and including 5,” establishing a prima facie case of obviousness.
Regarding claim 8, Okami teaches that the component B (which reads on the claimed component (E-2), has the following structure:
PNG
media_image1.png
137
210
media_image1.png
Greyscale
Formula (I) of Okami (US 5,104,919, col. 3, lines 1-6)
Wherein R represents a substituted or unsubstituted monovalent hydrocarbon group having from 1 to 6 carbon atoms excluding unsaturated aliphatic hydrocarbon groups and n represents an integer of 3 to 8 (col. 1, lines 56-60). This structure reads on the claimed “alkenyl-group-containing cyclic organopolysiloxane” because it is identical to the claimed structure when R is a methyl group.
Regarding claims 9 and 10, Okami teaches the incorporation of fumed silica (col. 6, lines 5-6) in amounts ranging from 3 to 500 parts by mass (col. 6, lines 1-6), which overlaps the claimed range of “5 to 100 parts by mass,” establishing a prima facie case of obviousness.
Regarding claims 11 and 12, Okami teaches the use of silica with a specific surface area of 200 m2/g (col. 8, line 44), which overlaps the claimed range of “50 m2/g or more, establishing a prima facie case of obviousness.
Regarding claims 13-18, Okami as modified is silent with regard to the claimed “T10” and “T90” characteristics. Nevertheless, Okami as applied above results in a composition that is structurally and compositionally identical to the claimed composition, which contains all of the same components in all of the required compositional amounts. Products of identical chemical compositions cannot have mutually exclusive properties. Where the claimed and prior art products are identical or substantially identical in structure or composition, a prima facie case of obviousness has been established. See MPEP 2112.01. The claimed “T10” and “T90” characteristics will therefore necessarily be present in Okami as modified and as applied above.
Regarding claims 19-26, Okami as modified is silent with regard to the claimed “η24” characteristic. Nevertheless, Okami as applied above results in a composition that is structurally and compositionally identical to the claimed composition, which contains all of the same components in all of the required compositional amounts. Products of identical chemical compositions cannot have mutually exclusive properties. Where the claimed and prior art products are identical or substantially identical in structure or composition, a prima facie case of obviousness has been established. See MPEP 2112.01. The claimed “η24” characteristic will therefore necessarily be present in Okami as modified and as applied above.
Response to Arguments
Applicant’s arguments, see Applicant’s Remarks, filed April 20, 2026, with respect to the rejection of claims 7-26 under 35 U.S.C. 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Okami, Kato, and Tasaki, as described above.
Conclusion
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSHUA CALEB BLEDSOE whose telephone number is (703)756-5376. The examiner can normally be reached Monday-Friday 8:00 a.m. - 5:00 p.m. EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Jones can be reached at 571-270-7733. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JOSHUA CALEB BLEDSOE/Examiner, Art Unit 1762
/ROBERT S JONES JR/Supervisory Patent Examiner, Art Unit 1762
Prosecution Insights